ISM-5059

Drug

Related News

Insilico Medicine Advances AI Drug Discovery Platform with New Partnership and Candidate Nomination

Mar 19, 2026

Insilico Medicine announced a partnership with China Medical System Holdings for AI-powered drug discovery and nominated ISM5059, an NLRP3-targeted drug candidate, for preclinical development following recent FDA IND approval for another AI-created drug.

Insilico Medicine Announces AI Foundation Model Partnership and China Drug Development Deal

Mar 04, 2026

Insilico Medicine has formed a strategic partnership with Liquid AI to develop lightweight scientific foundation models for drug discovery and entered a drug development collaboration with China Medical System Holdings targeting CNS and autoimmune diseases.